-transparent.png){kind=logo}
Ipratropium (40 micrograms) and theophylline (oxtriphylline 400 mg) were administered to 24 asthmatics in a randomized double-blind placebo controlled trial. The combination of these agents produced additive bronchodilation for up to two hours, with a 23 percent maximal increase in FEV1. This regimen promises to be safe, effective therapy for patients with asthma.
Related Publications
H Kreisman, and
C Cohen, and
H Ghezzo, and
F Vickerson, and
H Frank, and
N Wolkove
May 1981,
Thorax,
H Kreisman, and
C Cohen, and
H Ghezzo, and
F Vickerson, and
H Frank, and
N Wolkove
April 1983,
European journal of respiratory diseases,
H Kreisman, and
C Cohen, and
H Ghezzo, and
F Vickerson, and
H Frank, and
N Wolkove
February 1985,
European journal of respiratory diseases,
H Kreisman, and
C Cohen, and
H Ghezzo, and
F Vickerson, and
H Frank, and
N Wolkove
January 1998,
Canadian respiratory journal,
H Kreisman, and
C Cohen, and
H Ghezzo, and
F Vickerson, and
H Frank, and
N Wolkove
January 1986,
Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
H Kreisman, and
C Cohen, and
H Ghezzo, and
F Vickerson, and
H Frank, and
N Wolkove
June 1997,
Chest,
H Kreisman, and
C Cohen, and
H Ghezzo, and
F Vickerson, and
H Frank, and
N Wolkove
January 2000,
The Journal of the American Board of Family Practice,
H Kreisman, and
C Cohen, and
H Ghezzo, and
F Vickerson, and
H Frank, and
N Wolkove
January 1988,
Zeitschrift fur Erkrankungen der Atmungsorgane,
H Kreisman, and
C Cohen, and
H Ghezzo, and
F Vickerson, and
H Frank, and
N Wolkove
December 1984,
Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde,
H Kreisman, and
C Cohen, and
H Ghezzo, and
F Vickerson, and
H Frank, and
N Wolkove
April 1986,
European journal of respiratory diseases,
